Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: A Southwest Oncology Group study

Cancer Research

Volumn 58, Issue 6, 1998, Pages 1149-1158

  Ahnen, Dennis J ^a,b,h   Feigl, Polly ^c   Quan, Gang ^a   Fenoglio Preiser, Cecelia ^d   Lovato, Laura C ^c   Bunn Jr , Paul A ^a   Stemmerman, Grant ^d   Wells, John D ^e   Macdonald, John S ^f   Meyskens Jr , Frank L ^g  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c SW Oncology Group Statistical Center ^*  (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

^e UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^f TEMPLE UNIVERSITY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h Southwest Oncology Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; LEVAMISOLE; ONCOPROTEIN; PROTEIN P53;

ADULT; ANEUPLOIDY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE S PHASE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TUMOR SUPPRESSOR GENE;

CELL DIVISION; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DNA, NEOPLASM; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GENES, RAS; GENETIC MARKERS; HUMANS; LEVAMISOLE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLOIDIES; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0032521205     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Fielding, L. P., Phillips, R. K. S., Fry, J. S., and Hittinger, R. Prediction of outcome after curative resection for large bowel cancer. Lancet, 2: 904-907, 1986.
2. Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Goodman, P. J., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., Veeder, M. H., and Mailliard, J. A. Levamisole and flurouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med., 322: 352-358, 1990.
3. Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Tangen, C. M., Tormey, D. C., Glick, J. H., Veeder, M. H., and Mailliard, J. A. Fluorouracil plus levamisole as effective adjuvant therapy after resection for stage III colon carcinoma: a final report. Ann. Intern. Med., 122: 321-326, 1995.
4. Leichman, L., Lenz, H. J., Leichman, C. G., Groshen, S., Danenberg, K., Baranda, J., Spears, C. P., Boswell, W., Silberman, H., Ortega, A., Stain, S., Beart, R., and Danenberg, P. Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial. Eur. J. Cancer., 31: 1306-1310, 1995.
5. Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Nakamura, Y., White, R., Smits, A. M. M., and Bos, J. L. Genetic alterations during colorectal tumor development. N. Engl. J. Med., 319: 525-532, 1988.
6. Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., VanTuinen, P., Ledbetter, D. H., Baker, D. F., Nakamura, Y., White, R., and Vogelstein, B. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science (Washington DC), 244: 217-221, 1989.
7. Aaltonen, L. A., Peltomaki, P., Leach, F. S., Sistonen, P., Pylkkanen, L., Meckllin, J., Jarvinen, H., Powell, S. M., Jen, S., Hamilton, S. R., Peterson, G. M., Kinzler, K. W., Vogelstein, B., and de la Chapella, A. Clues to the pathogenesis of familial colorectal cancer. Science (Washington DC), 260: 812-816, 1993.
8. Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Tangen, C. M., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., Veeder, M. H., and Mailliard, J. A. The intergroup trial of fluorouracil plus levamisole as adjuvant therapy for stage II (Dukes' B-2) colon cancer. J. Clin. Oncol., 13: 2936-2943, 1995.
9. Orita, M., Suzuki, Y., Sekiya, T., and Hayashi, K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics, 15: 874-879, 1989.
10. Hedley, D. W., Friedlander, M. L., Taylor, I. W., Rug, C. A., and Musgrove, E. A. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J. Histochem. Cytochem., 31: 1333-1335, 1983.
11. Bauer, K. D., Bagwell, C. B., Giaretti, W., and Melamed, M. Consensus review of the clinical utility of DNA flow cytometry in colorectal cancer. Cytometry, 14: 486-491, 1993.
12. SAS Institute Inc. SAS/STAT Software. Changes and enhancements through release 6.11, Cary, NC: SAS Institute Inc., 1996.
13. SAS Institute Inc. SAS Technical Report P-217, SAS/STAT Software. The PHREG Procedure, version 6, Cary, NC: SAS Institute Inc., 1991.
14. Fleiss, J. L. Statistical Methods for Rates and Proportions. New York: John Wiley and Sons, 1973.
15. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
16. Cox, D. R. Regression models and life-tables. J. R. Stat. Soc. 34: 187-220, 1972.
17. Altman, D. G. Practical Statistics for Medical Research. New York: Chapman and Hall, 1991.
18. Forrester, K., Almoguera, C., Han, K., Grizzle, W. E., and Perucho, M. Detection of high incidence of K-ras oncogenes during human carcinogenesis. Nature (Lond.), 327: 298-303, 1987.
19. Burmer, G. C., and Loeb, L. A. Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma. Proc. Natl. Acad. Sci. USA, 86: 2403-2407, 1989.
20. Shaw, P., Tardy, S., Benito, E., Ogrador, A., and Costa J. Occurrence of Ki-ras and p53 mutations in primary colorectal tumors. Oncogene. 6: 2121-2128, 1991.
21. Halter, S. A., Webb, L., and Rose, J. Lack of ras mutations and prediction of long-term survival in carcinoma of the colon. Mod. Pathol., 5: 131-134, 1992.
22. Benhattar, J., Losi, L., Chaubert, P., Givel, J. C., and Costa, J. Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology, 104: 1044-1048, 1993.
23. Pricolo, V. E., Finkelstein, S. D., Wu, T., Keller, G., Bakker, A., Swalsky, P. A., and Bland, K. I. Prognostic value of TP53 and K-ras-2 mutational analysis in stage III carcinoma of the colon. Am. J. Surg., 171: 41-46, 1996.
24. Miyahara, M., Saito, T., Kaketani, K., Sato, K., Kuwahara, A., Shimoda, K., and Kogayashi, M. Clinical significance of ras 21 overexpression for patients with an advanced colorectal cancer. Dis. Colon Rectum, 34: 1097-102, 1992.
25. Laurent-Puig, P., Olschwang, S., Delattre, O., and Remuikos, Y. Survival and acquired genetic alterations in colorectal cancer. Gastroenterology, 102: 1136-1141, 1992.
26. Finlay, C. A., Hinds, P. W., Tan, T. H., Eliyahu, D., Oren, M., and Levine, A. J. Activating mutations for transformation by p53 produce a gene product that forms an hsc700 p53 complex with an altered half-life. Mol. Cell. Biol., 8: 531-539, 1988.
27. Baas, I. O., Mulder, J. W. R., Offerhaus, G. J. A., Vogelstein, B., and Hamilton, S. R. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J. Pathol., 172: 5-12, 1994.
28. Starzynska, T., Bromley, M., Ghosh, A., and Stern, P. L. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br. J. Cancer, 66: 558-62, 1992.
29. Bell, S. M., Scott, N., Cross, D., Sagar, P., Lewis, F. A., Blair, G. E., Taylor, G. R., Dixon, M. F., and Quirke, P. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology, 104: 57-64, 1993.
30. Yamaguchi, A., Kurosaka, Y., Fushida, S., Kanno, M., Yonemura, Y., Miwa, K., and Miyazaki, I. Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer (Phila.), 70: 2778-2784, 1992.
31. Scott, N., Sagar, P., Stewart, J., Blair, G. E., Dixon, M. F., and Quirke, P. p53 in colorectal cancer: clinicopathological correlation and prognostic significance. Br. J. Cancer. 63: 317-319, 1991.
32. Remvikos, Y., Tominaga, O., Hammel, P., Laurent-Puig, P., Salmon, R. J., Dutrillarx, B., and Thomas, G. Increased p53 protein content of colorectal tumours correlates with poor survival. Br. J. Cancer, 66: 758-764, 1992.
33. Bosari, S., Viale, G., Bosse, P., Maggione, M., Coggi, G., Murray, J. J., and Lee, A. K. C. Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. J. Natl. Cancer Inst., 86: 681-687, 1994.
34. Sun, X-F., Carstensen, J. M., Zhang, H., Stal, O., Wingren, S., Hatschek, T., and Nordenskjold, B. Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet, 340: 1369-1373, 1992.
35. Remvikos, Y., Laurent-Puig, P., Salmon, R. J., Frelat, G., Dutrillaux, B., and Thomas, G. Simultaneous monitoring of p53 protein and DNA content of colorectal adenocarcinomas by flow cytometry. Int. J. Cancer, 45: 450-456. 1990.
36. Mulder, J-W. R., Baas, I. O., Polak, M. M., Goodman, S. N., and Offerhaus, G. J. A. Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma. Br J Cancer, 71: 1257-1262, 11995.
37. Carbone, D. P., Mitsudomi, T., Chiba, I., Piantadosi, S., Rusch, V., Nowak, J. A., McIntire, D., Slamon, D., Gazdar, A., and Minna, J. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. Chest, 106: 377S-381S, 1994.
38. Nathanson, S. D., Linden, M. D., Tender, P., Zarbo, R. J., Jacobson, G., and Nelson, L. S. Relationship among p53, stage, and prognosis of large bowel cancer. Dis. Colon Rectum, 37: 527-534, 1994.
39. Hamelin, R., Laurent-Puig, P., Olschwang, S., Jego, N., Asselain, B., Remvikos, Y., Giroder, J., Salmon, R. J., and Thomas, G. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology, 106: 42-48, 1994.
40. Takanishi, D. M., Jr., Hart, J., Covarelli, P., Chappell, R., and Michelassi, F. Ploidy as a prognostic feature in colonic adenocarcinoma. Arch. Surg., 131: 587-592, 1996.
41. Harlow, S. P., Eriksen, B. L., Poggensee, L., Chmiel, J. S., Scarpelli, D. G., Murad, T., and Bauer, K. D. Prognostic implications of proliferative activity and DNA, aneuploidy in Astler-Coller Dukes stage C colonie adenocarcinomas. Cancer Res., 51: 2403-2409, 1991.
42. Scivetti, P., Danova, M., Riccardi, A., Fiocca, R., Dionigi, P., and Mazzini, G. Prognostic significance of DNA content in large bowel carcinoma: a retrospective flow cytometric study. Cancer Lett., 46: 213-219, 1989.
43. Schutte, B., Reynders, M. M., Wiggers, T., Arends, J. W., Volovics, L., Bosman, F. T., and Blijham, G. H. Retrospective analysis of the prognostic significance of DNA content and proliferative activity in large bowel carcinoma. Cancer Res., 47: 5494-5496, 1987.
44. Bauer, K. D., Lincoln, S. T., Vera-Roman, J. M., Wallemark, C. B., Chmiel, J. S., Madurski, M. L., Murad, T., and Scarpelli, D. G. Prognostic implications of proliferative activity and DNA aneuploidy in colonic adenocarcinomas. Lab. Invest., 57: 329-335, 1987.
45. Kokal, W., Sheibani, K., Terz, J., and Harada, J. R. Tumor DNA content in the prognosis of colorectal carcinoma. J. Am. Med. Assoc., 255: 3123-3127, 1986.
46. Melamed, M. R., Enker, W. E., Banner, P., Janov, A. J., Kessler, G., and Darzynkjewicz, Z. Flow cytometry of colorectal carcinoma with three-year follow-up. Dis. Colon Rectum, 29: 184-186, 1986.
47. Armitage, N. C., Robins, R. A., Evans, D. F., Turner, D. R., Baldwin, R. W., and Hardcastle, J. D. The influence of tumour cell DNA abnormalities on survival in colorectal cancer. Br. J. Surg., 72: 828-830, 1985.